Project Name,Region,Country,Site ID,Subject ID,Latest Visit (SV) (Source: Rave EDC: BO4),Subject Status (Source: PRIMARY Form),Input files,,,,,,,,,CPMD,,,,,,,,,,,,,,,,,,,,,,SSM,,,,,
,,,,,,,Missing Visits,Missing Page,# Coded terms,# Uncoded Terms,# Open issues in LNR,# Open Issues reported for 3rd party reconciliation in EDRR,Inactivated forms and folders,# eSAE dashboard review for DM,# eSAE dashboard review for safety,Visit status,Page status (Source: (Rave EDC : BO4)),,,,,Queries status (Source:(Rave EDC : BO4)),,,,,,,,Page Action Status (Source: (Rave EDC : BO4)),,,,,,Protocol Deviations (Source:(Rave EDC : BO4)),,PI Signatures (Source: (Rave EDC : BO4)),,,,,
,,,,,,,,,,,,,,,,# Expected Visits (Rave EDC : BO4),# Pages Entered,# Pages with Non-Conformant data,# Total CRFs with queries & Non-Conformant data,# Total CRFs without queries & Non-Conformant data,% Clean Entered CRF,# DM Queries,# Clinical Queries,# Medical Queries,# Site Queries,# Field Monitor Queries,# Coding Queries,# Safety Queries,#Total Queries,# CRFs Require Verification (SDV),# Forms Verified,# CRFs Frozen,# CRFs Not Frozen,# CRFs Locked,# CRFs Unlocked,# PDs Confirmed,# PDs Proposed,# CRFs Signed,CRFs overdue for signs within 45 days of Data entry,CRFs overdue for signs between 45 to 90 days of Data entry,CRFs overdue for signs beyond 90 days of Data entry,Broken Signatures,CRFs Never Signed
Responsible LF for action,,,,,,,,,,,,,,,,,,Site/CRA,,,,DM,CSE/CDD,CDMD/Medical Lead,Site/CRA,CRA,Coder,Safety Team,,CRA,,,DM,,,CD LF,,Investigator,,,,,
Study 19,ASIA,AUS,Site 109,Subject 835,Screening,Screening,,,,,,,,,,1,8,0,,,,0,0,0,1,0,0,0,1,0,4,0,0,0,0,0,0,7,0,0,0,0,0
Study 19,ASIA,AUS,Site 109,Subject 836,Cycle 1 Day 29 (1),On Trial,,,,,,,,,,5,60,0,,,,0,0,0,5,0,0,0,5,7,52,0,0,0,0,0,0,54,5,0,0,1,4
Study 19,ASIA,AUS,Site 109,Subject 837,Cycle 1 Day 15 (1),On Trial,,,,,,,,,,4,59,0,,,,0,0,0,21,0,0,0,21,10,21,0,0,0,0,0,0,48,8,0,0,1,7
Study 19,ASIA,AUS,Site 109,Subject 838,Cycle 1 Day 1 (1),On Trial,,,,,,,,,,3,50,0,,,,0,0,0,37,0,0,0,37,11,17,0,0,0,0,0,0,40,6,0,0,3,3
Study 19,ASIA,AUS,Site 109,Subject 839,Screening,Screening,,,,,,,,,,1,14,0,,,,0,0,0,1,0,0,0,1,1,6,0,0,0,0,0,0,0,9,0,0,0,9
Study 19,ASIA,AUS,Site 467,Subject 3553,Screening,Screening,,,,,,,,,,1,7,0,,,,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,6,0,0,0,6
Study 19,ASIA,AUS,Site 468,Subject 3560,Cycle 1 Day 29 (1),On Trial,,,,,,,,,,5,64,0,,,,1,2,0,3,1,0,0,7,20,42,0,0,0,0,0,0,43,18,0,0,13,5
Study 19,ASIA,AUS,Site 468,Subject 3561,Cycle 1 Day 15 (1),On Trial,,,,,,,,,,4,60,0,,,,3,5,0,15,0,0,0,23,21,15,0,0,0,0,0,0,28,29,0,0,15,14
Study 19,ASIA,AUS,Site 468,Subject 3562,Randomization (1),On Trial,,,,,,,,,,2,35,0,,,,1,10,0,6,0,0,0,17,18,6,0,0,0,0,0,0,15,19,0,0,10,9
Study 19,ASIA,AUS,Site 468,Subject 3563,Cycle 1 Day 1 (1),On Trial,,,,,,,,,,3,50,0,,,,1,0,0,12,2,0,0,15,16,18,0,0,0,0,0,0,10,35,0,0,2,33
Study 19,ASIA,AUS,Site 468,Subject 3564,Cycle 1 Day 15 (1),On Trial,,,,,,,,,,4,64,0,,,,0,0,0,21,4,0,0,25,40,3,0,0,0,0,0,0,16,36,0,0,2,34
Study 19,ASIA,AUS,Site 468,Subject 4880,Screening,Screening,,,,,,,,,,1,12,0,,,,0,0,0,15,0,0,0,15,2,6,0,0,0,0,0,0,4,5,0,0,1,4
Study 19,EMEA,FRA,Site 9,Subject 16,,,,,,,,,,,,0,1,0,,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Study 19,EMEA,FRA,Site 9,Subject 3512,Randomization (1),On Trial,,,,,,,,,,2,24,0,,,,0,0,0,2,0,0,0,2,11,0,0,0,0,0,0,0,0,21,0,0,0,21
Study 19,EMEA,DEU,Site 777,Subject 4881,,,,,,,,,,,,0,1,0,,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Study 19,EMEA,DEU,Site 777,Subject 4882,,,,,,,,,,,,0,1,0,,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Study 19,EMEA,DEU,Site 777,Subject 4883,,,,,,,,,,,,0,1,0,,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Study 19,EMEA,ISR,Site 778,Subject 4884,Cycle 2 Day 1 (1),On Trial,,,,,,,,,,6,72,1,,,,2,4,0,7,0,0,0,13,28,43,0,0,0,0,2,0,0,41,29,0,0,70
Study 19,EMEA,ISR,Site 778,Subject 4885,Screening,Screening,,,,,,,,,,1,9,0,,,,4,0,0,0,0,0,0,4,6,0,0,0,0,0,0,0,0,8,0,0,0,8
Study 19,EMEA,ISR,Site 778,Subject 4886,Cycle 1 Day 15 (1),On Trial,,,,,,,,,,4,38,0,,,,1,1,0,7,0,0,0,9,7,12,0,0,0,0,0,0,0,36,0,0,0,36
Study 19,EMEA,ISR,Site 779,Subject 4887,Screening,,,,,,,,,,,1,4,0,,,,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,3,0,0,0,3
Study 19,EMEA,ISR,Site 493,Subject 3670,Screening,,,,,,,,,,,1,5,0,,,,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,4,0,0,0,4
Study 19,EMEA,ISR,Site 493,Subject 3671,Screening,,,,,,,,,,,1,5,0,,,,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,4,0,0,0,4
Study 19,EMEA,ISR,Site 493,Subject 3672,Screening,Screening,,,,,,,,,,1,6,0,,,,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,5,0,0,0,5
Study 19,,PRK,Site 113,Subject 911,Cycle 1 Day 1 (1),On Trial,,,,,,,,,,3,56,0,,,,1,1,0,0,0,0,0,2,55,0,0,0,0,0,0,0,0,55,0,0,0,55
Study 19,,PRK,Site 113,Subject 912,Unplanned Visit (3),On Trial,,,,,,,,,,2,69,0,,,,0,7,0,0,0,0,0,7,30,0,0,0,0,0,0,0,0,65,0,0,0,65
Study 19,,PRK,Site 113,Subject 913,Randomization (1),On Trial,,,,,,,,,,2,43,0,,,,0,0,0,1,0,0,0,1,27,0,0,0,0,0,0,0,0,42,0,0,0,42
Study 19,,PRK,Site 113,Subject 914,Unplanned Visit (1),Screening,,,,,,,,,,1,38,0,,,,0,0,0,1,0,0,0,1,22,0,0,0,0,0,0,0,0,36,0,0,0,36
Study 19,ASIA,KOR,Site 417,Subject 3227,Randomization (1),On Trial,,,,,,,,,,2,29,0,,,,0,0,0,2,0,0,0,2,28,0,0,0,0,0,0,0,0,28,0,0,0,28
Study 19,ASIA,KOR,Site 417,Subject 3228,Screening,Screening,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,5,0,0,0,5
Study 19,ASIA,KOR,Site 417,Subject 3229,Screening,Screening,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,8,0,0,0,8
Study 19,ASIA,SGP,Site 780,Subject 4888,Screening,Screening,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,8,0,0,0,0,0,0,0,8,0,0,0,0,0
Study 19,ASIA,SGP,Site 780,Subject 4889,Screening,Screening,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,7,0,0,0,0,0,0,0,8,0,0,0,0,0
Study 19,ASIA,SGP,Site 780,Subject 4890,Cycle 3 Day 15 (1),On Trial,,,,,,,,,,11,114,0,,,,3,1,0,4,0,0,0,8,36,55,0,0,0,0,0,0,109,0,0,0,0,0
Study 19,ASIA,SGP,Site 780,Subject 4891,End of Treatment (1),On Trial,,,,,,,,,,10,94,0,,,,1,0,0,0,0,0,0,1,40,23,0,0,0,0,0,0,90,1,0,0,1,0
Study 19,ASIA,SGP,Site 780,Subject 4892,Cycle 2 Day 29 (1),On Trial,,,,,,,,,,9,89,0,,,,0,1,0,2,0,0,1,4,33,32,0,0,0,0,0,0,78,5,0,0,2,3
Study 19,ASIA,SGP,Site 780,Subject 4893,Cycle 2 Day 29 (1),On Trial,,,,,,,,,,9,88,0,,,,2,5,0,1,0,0,0,8,31,32,0,0,0,0,1,0,84,2,0,0,1,1
Study 19,ASIA,SGP,Site 780,Subject 4894,Screening,Screening,,,,,,,,,,1,8,0,,,,0,0,0,0,0,0,0,0,5,1,0,0,0,0,0,0,7,0,0,0,0,0
Study 19,ASIA,SGP,Site 780,Subject 4895,Unplanned Visit (6),On Trial,,,,,,,,,,7,132,0,,,,0,3,0,5,0,0,0,8,46,19,0,0,0,0,0,0,107,7,1,0,7,1
Study 19,ASIA,SGP,Site 780,Subject 4896,Screening,Screening,,,,,,,,,,1,5,0,,,,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,4,0,0,0,0,0
Study 19,ASIA,SGP,Site 780,Subject 4897,Screening,Screening,,,,,,,,,,1,5,0,,,,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,4,0,0,0,0,0
Study 19,ASIA,TWN,Site 155,Subject 1427,Screening,Screening,,,,,,,,,,1,5,0,,,,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,4,0,0,0,4
Study 19,ASIA,TWN,Site 155,Subject 1428,Screening,Screening,,,,,,,,,,1,5,0,,,,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,4,0,0,0,4
Study 19,AMERICA,USA,Site 781,Subject 4898,Screening,Screening,,,,,,,,,,1,4,0,,,,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,3,0,0,0,3
Study 19,AMERICA,USA,Site 782,Subject 4899,Cycle 2 Day 15 (1),On Trial,,,,,,,,,,8,118,0,,,,1,1,0,0,5,0,0,7,50,64,0,0,0,0,0,0,71,43,0,0,6,37
Study 19,AMERICA,USA,Site 782,Subject 4900,Randomization (1),Discontinued,,,,,,,,,,2,50,0,,,,0,0,0,0,2,0,0,2,1,23,0,0,0,0,0,0,46,2,0,0,1,1
Study 19,AMERICA,USA,Site 782,Subject 4901,Cycle 1 Day 15 (1),On Trial,,,,,,,,,,4,73,0,,,,1,3,0,0,0,0,0,4,36,0,0,0,0,0,0,0,20,49,0,0,8,41
Study 19,AMERICA,USA,Site 782,Subject 4902,Screening,Screening,,,,,,,,,,1,13,0,,,,0,0,0,1,0,0,0,1,7,0,0,0,0,0,0,0,0,9,0,0,0,9
,,,14,48,Total:,,,,,,,,,,,132,1727,1,,,,22,44,0,170,14,0,1,251,701,494,0,0,,,,,901,666,30,0,74,622
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
